Samsung Pharmaceutical submits domestic phase 2/3 clinical trial plan for progressive nuclear palsy

삼성제약, 진행성핵상마비 국내 2b/3상 임상시험계획서 제출

6 reports from 6 outlets in 1 language · first reported 2026-09-28 00:53 UTC · updated 2026-09-28 08:35 UTC · JSON

Reports

1. 삼성제약, 진행성핵상마비 국내 2b/3상 임상시험계획서 제출Samsung Pharmaceutical submits domestic phase 2/3 clinical trial plan for progressive nuclear palsyPublished by mk.co.kr, mt.co.kr · 2026-09-28 08:30 UTC
2. 삼성제약 "진행성핵상마비 국내 2b·3상 계획제출"Samsung Pharmaceutical 'Progressive nuclear palsy domestic phase 2 and 3 plans submitted'newsis.com · ko · 2026-09-28 08:35 UTC
3. 삼성제약, ‘GV1001’ 진행성핵상마비 국내 2b/3상 IND 제출…“적응적 설계 도입”Samsung Pharmaceutical submitted IND for progressive nuclear palsy 'GV1001' in domestic phase 2b/3... 'Introducing adaptive design'etoday.co.kr · ko · 2026-09-28 08:31 UTC
4. 삼성제약, 진행성핵상마비 신약 국내 2b/3상 승인 신청Samsung Bioepis applies for domestic phase 2b/3 approval for new drug for progressive nuclear palsycdn.medipana.com · ko · 2026-09-28 08:25 UTC
5. 삼성제약, 진행성핵상마비 3상 IND 재신청 예정Samsung Bioepis Resubmits Phase 3 IND for Progressive Supranuclear Palsybosa.co.kr · ko · 2026-09-28 00:53 UTC